Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

NCT03224767 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT03224767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03224767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 5, 2018
Completion date
August 1, 2028
Enrollment
24 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e mutation present, papillary craniopharyngioma